Lifesci Capital Has Pessimistic Outlook of LQDA Q3 Earnings

Liquidia Technologies, Inc. (NASDAQ:LQDA) – Analysts at Lifesci Capital dropped their Q3 2025 earnings per share (EPS) estimates for Liquidia Technologies in a research note issued to investors on Tuesday, August 12th. Lifesci Capital analyst C. Jubinville now expects that the company will post earnings of ($0.50) per share for the quarter, down from their previous forecast of ($0.39). The consensus estimate for Liquidia Technologies’ current full-year earnings is ($1.51) per share. Lifesci Capital also issued estimates for Liquidia Technologies’ Q4 2025 earnings at ($0.29) EPS and FY2025 earnings at ($1.89) EPS.

Liquidia Technologies (NASDAQ:LQDA) last announced its quarterly earnings results on Tuesday, August 12th. The company reported ($0.49) earnings per share (EPS) for the quarter, missing the consensus estimate of ($0.43) by ($0.06). Liquidia Technologies had a negative return on equity of 232.96% and a negative net margin of 732.17%. The company had revenue of $8.84 million for the quarter, compared to the consensus estimate of $3.90 million. The company’s quarterly revenue was up 141.5% compared to the same quarter last year.

A number of other brokerages have also recently commented on LQDA. Needham & Company LLC upped their price target on Liquidia Technologies from $32.00 to $36.00 and gave the company a “buy” rating in a research report on Tuesday. HC Wainwright increased their price objective on Liquidia Technologies from $29.00 to $35.00 and gave the stock a “buy” rating in a report on Wednesday, May 28th. Oppenheimer set a $13.00 target price on Liquidia Technologies and gave the stock an “underperform” rating in a research note on Monday, May 19th. Scotiabank upped their target price on Liquidia Technologies from $36.00 to $37.00 and gave the stock a “sector outperform” rating in a research note on Wednesday, May 28th. Finally, Raymond James Financial upped their target price on Liquidia Technologies from $33.00 to $41.00 and gave the stock a “strong-buy” rating in a research note on Wednesday. One analyst has rated the stock with a sell rating, one has issued a hold rating, seven have issued a buy rating and two have assigned a strong buy rating to the company. According to MarketBeat.com, the stock has an average rating of “Moderate Buy” and an average target price of $31.40.

Liquidia Technologies Stock Down 0.5%

LQDA stock opened at $25.95 on Friday. Liquidia Technologies has a 1-year low of $8.26 and a 1-year high of $26.65. The company has a current ratio of 2.49, a quick ratio of 2.91 and a debt-to-equity ratio of 9.84. The stock’s fifty day simple moving average is $16.30 and its two-hundred day simple moving average is $15.52. The stock has a market cap of $2.23 billion, a P/E ratio of -15.26 and a beta of 0.14.

Insider Activity

In related news, insider Scott Moomaw sold 4,797 shares of the stock in a transaction dated Monday, July 14th. The stock was sold at an average price of $14.28, for a total transaction of $68,501.16. Following the completion of the sale, the insider directly owned 223,231 shares in the company, valued at $3,187,738.68. This represents a 2.10% decrease in their position. The sale was disclosed in a legal filing with the SEC, which is available through this link. Also, CEO Roger Jeffs sold 20,252 shares of the stock in a transaction dated Monday, July 14th. The shares were sold at an average price of $14.28, for a total value of $289,198.56. Following the sale, the chief executive officer owned 1,038,560 shares of the company’s stock, valued at $14,830,636.80. This represents a 1.91% decrease in their ownership of the stock. The disclosure for this sale can be found here. In the last three months, insiders sold 90,277 shares of company stock worth $1,469,392. 26.50% of the stock is currently owned by insiders.

Institutional Investors Weigh In On Liquidia Technologies

Several institutional investors and hedge funds have recently bought and sold shares of LQDA. Cetera Investment Advisers lifted its stake in shares of Liquidia Technologies by 4.3% in the 4th quarter. Cetera Investment Advisers now owns 31,243 shares of the company’s stock valued at $367,000 after purchasing an additional 1,277 shares during the period. Deutsche Bank AG lifted its stake in shares of Liquidia Technologies by 53.4% in the 4th quarter. Deutsche Bank AG now owns 51,075 shares of the company’s stock valued at $601,000 after purchasing an additional 17,790 shares during the period. Raymond James Financial Inc. purchased a new position in shares of Liquidia Technologies in the 4th quarter valued at approximately $218,000. Millennium Management LLC purchased a new position in shares of Liquidia Technologies in the 4th quarter valued at approximately $526,000. Finally, GAMMA Investing LLC lifted its stake in shares of Liquidia Technologies by 2,342.7% in the 1st quarter. GAMMA Investing LLC now owns 43,675 shares of the company’s stock valued at $644,000 after purchasing an additional 41,887 shares during the period. Hedge funds and other institutional investors own 64.54% of the company’s stock.

About Liquidia Technologies

Liquidia Corporation, a biopharmaceutical company, develops, manufactures, and commercializes various products for unmet patient needs in the United States. Its lead product candidates include YUTREPIA, an inhaled dry powder formulation of treprostinil for the treatment of pulmonary arterial hypertension (PAH) and pulmonary hypertension associated with interstitial lung disease (PH-ILD).